We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Impact of metformin on anti-Müllerian hormone in women with polycystic ovary syndrome: a secondary analysis of a randomized controlled trial.
- Authors
Madsen, Helen N.; Lauszus, Finn F.; Trolle, Birgitta; Ingerslev, Hans J.; Tørring, Niels
- Abstract
Conclusions on the effect of metformin on circulating anti-Müllerian hormone ( AMH) levels in women with polycystic ovary syndrome ( PCOS) are ambiguous. We performed a secondary analysis of a randomized, double-blind, placebo-controlled cross-over trial. Fifty-six women with hyperandrogenemic PCOS were included. Each woman served as her own control receiving a daily dose of either 1700 mg metformin or placebo for 6 months. After a 3-month wash-out period they received the opposite treatment. The decrease in AMH from a median of 49.5 to 46.9 pmol/L after 6 months on metformin was overall not significant ( p = 0.81), nor were changes in obese women (from 49.5 to 38.2 pmol/L; p = 0.53). Comparing individual metformin/placebo AMH values, a small absolute decrease of 9.3 pmol/L ( p = 0.03) was observed in obese women after 6 months relative to baseline, suggesting a trend towards decreasing values after metformin treatment, mainly in obese women.
- Subjects
ANTI-Mullerian hormone; METFORMIN; POLYCYSTIC ovary syndrome; OBESITY in women; RANDOMIZED controlled trials; THERAPEUTICS
- Publication
Acta Obstetricia et Gynecologica Scandinavica, 2015, Vol 94, Issue 5, p547
- ISSN
0001-6349
- Publication type
Article
- DOI
10.1111/aogs.12605